- OXOPYRIDO[1,2-A]PYRIMIDINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION
-
The present invention relates to novel compounds of formula (I), wherein R1 to R7 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
- -
-
Page/Page column 35; 36
(2020/07/14)
-
- NOVEL COMPOUNDS
-
The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic group which in turn is substituted at the α-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
- -
-
Page/Page column 328; 329
(2019/11/19)
-
- Novel Compounds
-
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
- -
-
Page/Page column 61
(2017/07/06)
-
- Synthesis and antibacterial activity of novel 1 β-methyl carbapenems with cycloalkylamine moiety at the C-2 position
-
Novel 1β-methyl carbapenems with a cycloalkylamine moiety as a side chain were synthesized and their structure-activity relationships were studied. These carbapenems showed potent antibacterial activities against a wide range of range of Gram-positive and Gram-negative bacteria, and moderate urinary recovery when administered intraperitoneally in mice.
- Kawamoto, Isao,Shimoji, Yasuo,Kanno, Osamu,Endo, Rokuro,Miyauchi, Masau,Kojima, Katsuhiko,Ishikawa, Katsuya,Morimoto, Munetsugu,Ohya, Satoshi
-
p. 1080 - 1092
(2007/10/03)
-
